spacer
home > > autumn 2003 > eea - an overview of requirements impacting industry
PUBLICATIONS


EEA - An Overview of Requirements Impacting Industry

Pharmacovigilance requirements in the EU are laid down in a variety of different documents, applicable according to the status and route of authorisation (such as pre- or post-approval, centrally or nationally approved). As it can be difficult for experienced personnel in this field, yet alone a newcomer, to digest these overlapping and detailed requirements, this article provides an overview of the reporting requirements applicable to the Marketing Authorisation Holder (MAH); gives sources for further information; and reviews possible changes arising as part of the current legislative review and as the EU moves towards enlargement.

The Basic Framework

Pharmacovigilance requirements in the EU are laid down in EU Regulations (540/95 (1) and 2309/93 (2), EU Directives 65/65 (3), 75/319 (4), 2000/38 (5) and 2001/83 (6)) and EU Guidelines (for example Notice to Marketing Authorisation Holders: Volume 9 - Pharmacovigilance Guidelines (7). There are also several policy papers relating to more specific functions, for example the concept paper on monitoring compliance (CPMP (Committee for Proprietary Medicinal Products) /PhVWP (Pharmacovigilance Working Party)/1618/01 (8)) and the EMEA (European Medicines Evaluation Agency) policy paper on electronic transmission (EMEA/H/5255/01 (9)). In addition, the EU Clinical Trials Directive (2001/20/EC (10)) lays down the basis for reporting from the clinical study environment, with relevant guidances currently being finalised.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Margaret Walters, Director of Pharmacovigilance at Merck Sharp & Dohme

Margaret Walters is currently Director of the European Office of Pharmacovigilance for Merck Sharp & Dohme Ltd. She has more than 16 years' experience in many areas of pharmacovigilance along with a further 10 years in basic research at Wellcome. Margaret is a member of the EFPIA Pharmacovigilance Ad Hoc group, co-chairs the PhRMA (EU) Pharmacovigilance team, is active in the EMEA/EFPIA Joint Working Party on Electronic Submissions and was part of the original (pre-ICH) MCA MedDRA Working Party.

She is also the author of several papers and her academic links include acting as External Adviser to the Postgraduate Diploma in Pharmacovigilance at the University of Hertfordshire.

spacer
Margaret Walters
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Leading pharma packaging companies commit to supply for Covid-19 fight

The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment that is developed, and that no patient shall be left behind, no matter what region of the world they live in. Also, the companies will make every effort to support the pharma industry’s’ priorities for overall medication supply in addition to Covid-19 drugs. Each of the three companies manufactures billions of type-1 borosilicate glass vials, the most proven and most widely available material used to store and deliver vaccines around the world. They are making the statement to provide confidence in the global pharmaceutical supply chain in times of uncertainty.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement